公开(公告)号：US20250082726A1

公开(公告)日：2025-03-13

申请号：US18959137

申请日：2024-11-25

Applicant: AMGEN INC.

Inventor： Yael WEXLER-COHEN ,  William J. CALLAHAN ,  Robert Matthew FESINMEYER ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

公开(公告)号：US20200338164A1

公开(公告)日：2020-10-29

申请号：US16764463

申请日：2018-11-16

Applicant: Amgen Inc.

Inventor： Yael WEXLER-COHEN ,  William J. CALLAHAN ,  Robert Matthew FESINMEYER ,  Rahul Rajan KAUSHIK ,  Sai Chakradhar PADALA

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34 ,  A61K47/02

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.

公开(公告)号：US20230151086A1

公开(公告)日：2023-05-18

申请号：US17820958

申请日：2022-08-19

Applicant: Amgen Inc.

Inventor： William J. CALLAHAN ,  Rahul Rajan KAUSHIK ,  Joy BRENNAN

IPC: C07K16/24 ,  A61K47/10 ,  A61K47/18

CPC classification number: C07K16/241 ,  A61K47/10 ,  A61K47/183 ,  A61K9/0019

Abstract: Stable adalimumab formulations are disclosed.

公开(公告)号：US20200087390A1

公开(公告)日：2020-03-19

申请号：US16471492

申请日：2017-12-20

Applicant: AMGEN INC.

Inventor： William J. CALLAHAN ,  Rahul Rajan KAUSHIK ,  Joy BRENNAN

IPC: C07K16/24 ,  A61K47/10 ,  A61K47/18

Abstract: Stable adalimumab formulations are disclosed.

公开(公告)号：US20160143852A1

公开(公告)日：2016-05-26

申请号：US15011229

申请日：2016-01-29

Applicant: AMGEN INC.

Inventor： William J. CALLAHAN ,  Richard L. REMMELE, Jr. ,  Gayathri RATNASWAMY ,  Ramil F. LATYPOV ,  Dingjiang LIU

IPC: A61K9/19 ,  A61K47/26 ,  A61K38/16 ,  A61K47/22

CPC classification number: A61K9/19 ,  A61K38/10 ,  A61K38/16 ,  A61K47/22 ,  A61K47/26 ,  C07K2319/30

Abstract: The present invention provides long-term stable formulations of a lyophilized therapeutic peptibody and methods for making a lyophilized composition comprising a therapeutic peptibody.

Abstract translation: 本发明提供了冻干治疗肽的长期稳定制剂和制备包含治疗性肽抗体的冻干组合物的方法。